Redundancy of IL-1 isoform signaling and its implications for arterial remodeling

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Beltrami Moreira, Marina ^a   Vromman, Amélie ^a   Sukhova, Galina K ^a   Folco, Eduardo J ^a   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CATHEPSIN S; CD68 ANTIGEN; ENZYME PRECURSOR; GELATINASE B; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; ISOPROTEIN; STROMELYSIN; CATHEPSIN; INTERLEUKIN 1; MESSENGER RNA; MMP1 PROTEIN, HUMAN;

ARTERIAL REMODELING; ARTERY DISEASE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; ENZYME RELEASE; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ARTERY; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; SECRETION (PROCESS); SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; CATHEPSINS; CELL MOVEMENT; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICE; MUSCLE, SMOOTH, VASCULAR; PROTEIN ISOFORMS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84977625171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152474     Document Type: Article

References (32)

1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013; 368(21):2004-13. doi: 10.1056/NEJMra1216063 PMID: 23697515
2. Fukumoto Y, Deguchi JO, Libby P, Rabkin-Aikawa E, Sakata Y, Chin MT, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation. 2004; 110(14):1953-9. PMID: 15451791
3. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, et al. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation. 2005; 112(17):2708-15. PMID: 16230484
4. Clinton SK, Fleet JC, Loppnow H, Salomon RN, Clark BD, Cannon JG, et al. Interleukin-1 gene expression in rabbit vascular tissue in vivo. Am J Pathol. 1991; 138(4):1005-14. PMID: 2012168
5. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009; 27:519-50. doi: 10.1146/annurev.immunol.021908.132612 PMID: 19302047
6. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94:2493-503. PMID: 7989608
7. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998; 102 (3):576-83. PMID: 9691094
8. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Annals of the New York Academy of Sciences. 1995; 748:501-7. PMID: 7695193
9. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest. 2012; 122(1):70-9. doi: 10.1172/JCI43713 PMID: 22201681
10. Glagov S, Weisenberg E, Zarins C, Stankunavicius R, Kolletis G. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987; 316:371-5.
11. Quillard T, Araujo HA, Franck G, Tesmenitsky Y, Libby P. Matrix metalloproteinase-13 predominates over matrix metalloproteinase-8 as the functional interstitial collagenase in mouse atheromata. Arterioscler Thromb Vasc Biol. 2014; 34(6):1179-86. doi: 10.1161/ATVBAHA.114.303326 PMID: 24723558
12. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991; 88 (18):8154-8. PMID: 1896464
13. Schoenhagen P, Vince DG, Ziada KM, Kapadia SR, Lauer MA, Crowe TD, et al. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol. 2002; 89(12):1354-9. PMID: 12062727
14. Rader DJ. IL-1 and atherosclerosis: a murine twist to an evolving human story. J Clin Invest. 2012; 122 (1):27-30. doi: 10.1172/JCI61163 PMID: 22201674
15. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012; 11(8):633-52. doi: 10.1038/nrd3800 PMID: 22850787
16. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013; 111(10):1394-400. doi: 10.1016/j.amjcard.2013.01.287 PMID: 23453459
17. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010; 105(10):1371-7 e1. doi: 10.1016/j.amjcard.2009.12.059 PMID: 20451681
18. Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014; 113(2):321-7. doi: 10.1016/j.amjcard.2013.08.047 PMID: 24262762
19. Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014; 7(4):619-28. doi: 10.1161/CIRCIMAGING.113.001193 PMID: 24782115
20. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008; 117(20):2662-9. doi: 10.1161/CIRCULATIONAHA.107.731877 PMID: 18474811
21. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162(4):597-605. doi: 10.1016/j.ahj.2011.06.012 PMID: 21982649
22. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012; 126(23):2739-48. doi: 10.1161/CIRCULATIONAHA.112.122556 PMID: 23129601
23. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. Journal of cellular physiology. 1983; 115(2):217-23. PMID: 6302107
24. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999; 274(17):11924-9. PMID: 10207013
25. Galis Z, Muszynski M, Sukhova G, Simon-Morrisey E, Unemori E, Lark M, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994; 75(1):181-9. PMID: 8013077
26. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages. Implications for imaging atherosclerosis with FdG-PET. J Am Coll Cardiol. 2011; 58(6):603-14. doi: 10.1016/j.jacc.2011.03.044 PMID: 21798423
27. Libby P, O'Brien KV. Culture of quiescent vascular smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983; 115:217-23. PMID: 6302107
28. Principal Components in Regression Analysis. In: Jolliffe IT, editor. Principal Component Analysis. New York: Springer; 2002. p. 167-98.
29. Johnson JL. Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis. Cardiovasc Res. 2014; 103(4):452-60. doi: 10.1093/cvr/cvu171 PMID: 25053639
30. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012; 95(2):194-204. doi: 10.1093/cvr/cvs135 PMID: 22467316
31. Loppnow H, Libby P. Functional significance of human vascular smooth muscle cell-derived interleukin1 in paracrine and autocrine regulation pathways. Exp Cell Res. 1992; 198:283-90. PMID: 1729135
32. Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation. 2008; 117(20):2577-9. doi: 10.1161/CIRCULATIONAHA.108.772491 PMID: 18490534